SILENCE THERAP. SP.ADR/1 (XRP2) — Capital Reinvestment Ratio

Latest as of December 2021: 0.20x

SILENCE THERAP. SP.ADR/1 (XRP2) has a Capital Reinvestment Ratio of 0.20x as of December 2021, meaning it reinvests 0% of its operating cash flow (€9.19 Million) in capital expenditures (€1.80 Million). Check tangible equity quality of SILENCE THERAP. SP.ADR/1 to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.20x

Capex / Operating Cash Flow

Operating Cash Flow

€9.19 Million

EUR

Capital Expenditures

€1.80 Million

EUR

Data as of

Dec 2021

Most recent filing

SILENCE THERAP. SP.ADR/1 Capital Reinvestment Ratio (2021–2021)

This chart tracks SILENCE THERAP. SP.ADR/1's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see SILENCE THERAP. SP.ADR/1 cash conversion from operations.

Annual Capital Reinvestment Ratio for SILENCE THERAP. SP.ADR/1 (2021–2021)

Year-by-year Capital Reinvestment Ratio for SILENCE THERAP. SP.ADR/1 from 2021 to 2021. See SILENCE THERAP. SP.ADR/1 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2021	0.20x	€9.19 Million	€1.80 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow